Invented by Wenshe Liu, Wei Wan, Suzhou Kunpeng Biotech Co Ltd
The market for fusion proteins and their use has been rapidly growing in recent years, with significant advancements in biotechnology and pharmaceutical research. Fusion proteins are created by combining two or more different proteins to form a single functional unit with enhanced properties and capabilities. This innovative approach has opened up new possibilities in various fields, including therapeutics, diagnostics, and research.
One of the primary applications of fusion proteins is in the field of therapeutics. By combining different proteins, scientists can create novel molecules with improved efficacy, stability, and specificity. Fusion proteins have been successfully used in the treatment of various diseases, including cancer, autoimmune disorders, and genetic disorders. For example, the fusion protein etanercept (trade name Enbrel) is widely used to treat rheumatoid arthritis and other inflammatory conditions. It combines the extracellular domain of a human tumor necrosis factor receptor with the Fc region of a human immunoglobulin G1 antibody, resulting in a molecule that can effectively neutralize tumor necrosis factor-alpha, a key mediator of inflammation.
In addition to therapeutics, fusion proteins have also found applications in diagnostics. They can be used as powerful tools for detecting and monitoring diseases. For instance, fusion proteins can be engineered to include a specific targeting moiety, such as an antibody or a receptor ligand, along with a reporter molecule, such as a fluorescent protein or an enzyme. This allows for the precise detection and visualization of specific biomarkers or targets in biological samples. Fusion proteins have been utilized in various diagnostic techniques, including immunohistochemistry, flow cytometry, and enzyme-linked immunosorbent assays (ELISA).
Furthermore, fusion proteins have proven to be invaluable in research and development. They enable scientists to study the function and interactions of proteins in a more controlled and efficient manner. By fusing proteins of interest with tags or markers, researchers can easily track and purify these proteins, facilitating their characterization and analysis. Fusion proteins have also been used to create novel tools for gene expression, protein-protein interactions, and protein localization studies. These tools have greatly contributed to our understanding of biological processes and have accelerated the discovery of new drugs and therapies.
The market for fusion proteins is expected to continue its growth trajectory in the coming years. Advancements in protein engineering techniques, such as recombinant DNA technology and protein expression systems, have made the production of fusion proteins more accessible and cost-effective. Moreover, the increasing demand for personalized medicine and targeted therapies is driving the development of novel fusion proteins with enhanced specificity and efficacy.
Several pharmaceutical and biotechnology companies are actively involved in the development and commercialization of fusion proteins. These companies are investing heavily in research and development to expand their product pipelines and meet the growing demand for innovative therapeutics and diagnostics. Additionally, collaborations between academia and industry are fostering the discovery and development of new fusion proteins with diverse applications.
In conclusion, the market for fusion proteins and their use is expanding rapidly, driven by advancements in biotechnology, pharmaceutical research, and the need for more effective therapeutics and diagnostics. Fusion proteins have demonstrated their potential in various fields, including therapeutics, diagnostics, and research. As the understanding of protein engineering and the demand for personalized medicine continues to grow, the market for fusion proteins is poised for further growth and innovation.
The Suzhou Kunpeng Biotech Co Ltd invention works as follows
The present disclosure relates to methods for producing recombinant proteins that contain between 10 and a 200 amino acid residues by using novel carrier protein derived from superfolder and its mutants.
Background for Fusion proteins and their use
Example 1. “Example 1.
Example 2″: Construction of Expression vector pSFGFPC – MCS
Example 3″: Construction of Expression vector pSFGFPN Prolispro
Example 4 : Construction of Expression vector pSFGFPN – Proinsulin
Example 5 : Construction of Expression vector pSFGFP Proglargine
Example 6 : Construction of Expression vector pSFGFPC
Example 8: Construction of Expression vector pSFGFPC – Calcitonin
Example 8″: Construction of expression vector pSFGFPCGLP1
Example 9 : Expression of Prolispro
Example 10 – Processing the Prolispro Fusion Protein to obtain Mature Lispro
Example 11 : Expression of the Proinsulin – sfGFP Fusion Protein
Example 12 : Expression of the Proglargine – sfGFP Fusion Protein
Example 13 : Expression of the PTH-sfGFP Fusion Protein
Example 14 : Expression of sfGFP – Calcitonin Fusion protein
Example 15 : Expression of GLP-1
INCORPORATION BY RESEARCH
to view the patent on Google Patents.